Pharmaceutical Wastewater Treatment in Thailand (2026 Process Guide)
Pharmaceutical wastewater in Thailand is typically treated with a five-stage train — equalization, primary clarification/DAF, anaerobic biological treatment, MBR, and a polishing AOP or UV stage — followed by RO for reuse. Effluent targets BOD ≤20 mg/L, COD ≤120 mg/L, TSS ≤50 mg/L, and pH 5.5–9.0 under the Thai FDA industrial effluent notification, with MBR removing 80–90% of API load before final oxidation.
Why Pharmaceutical Wastewater Hits Harder in Thailand
Thailand's API manufacturing base sits in clusters — the Bangkok metropolitan industrial ring and the Eastern Seaboard estates around Rayong and Map Ta Phut — and the wastewater profile from these plants is fundamentally different from hospital or municipal effluent. A typical Thai API plant discharges a mixed stream of synthesis mother liquors, solvent wash waters, fermentation broths, and CIP rinses, with peak flows that swing 3–5× between batch campaigns. Production scale is real: a mid-sized API facility in Thailand generates 100–2,000 m³/day of process wastewater, which is orders of magnitude above the 1,500 L/bed/day figure that WHO attributes to healthcare facilities.
The chemistry is what makes this stream hard to treat. Antibiotic concentrations in API manufacturing wastewater run 26 ng/L–31 mg/L (Larsson et al., 2007; Okeke et al., 2022) — roughly 1,000× higher than the 0.1–157 μg/L range measured in hospital effluent. Even at formulation-only plants, 30–90% of administered antibiotics pass through human metabolism unchanged (Carvalho and Santos, 2016) and end up in plant effluent. When you combine that with high BOD/COD, volatile solvents, and occasional pH excursions, a generic municipal-grade treatment train cannot meet Thai discharge requirements.
Thailand's 2026 Effluent Compliance Baseline
The enforceable baseline for industrial effluent in Thailand is the Thai FDA Notification B.E. 2556 (2013) on industrial effluent standards, administered and updated through the Pollution Control Department (PCD). The 2026 posture keeps the same numeric ceilings while tightening toxicity-test enforcement, particularly for plants discharging to the Chao Phraya, Bang Pakong, or Map Ta Phut coastal outfalls. A plant owner who designs only to BOD/COD is exposed on toxicity grounds, which is why advanced polishing is now standard practice rather than optional.
| Parameter | Limit (Thai FDA / PCD) | Engineering implication |
|---|---|---|
| BOD | ≤20 mg/L | Biological stage must remove >95% |
| COD | ≤120 mg/L | MBR + AOP needed for recalcitrant APIs |
| TSS | ≤50 mg/L | DAF or membrane separation required |
| pH | 5.5–9.0 | Equalization with pH trim mandatory |
| Oil & grease | ≤5 mg/L | Skim + DAF upstream of biology |
| Residual chlorine | ≤1 mg/L | Dechlorination or UV (not free Cl₂) |
| Heavy metals (Cd, Hg, Pb, Cr) | Site-specific, low ppm range | Precipitation + sludge handling |
| TDS / salinity | Triggered for coastal receivers | RO polish required for discharge to Map Ta Phut outfalls |
A single numeric limit for "API in effluent" does not yet exist in the Thai notification. Operators are judged on BOD, COD, TSS, and on whole-effluent toxicity tests, which is why AOP polishing — UV/H₂O₂ or O₃ — has moved from optional to effectively required for plants that handle antibiotics, hormones, or cytotoxics. The table above is the working set of numbers a 2026 EHS manager should paste into a permit review before sizing a single tank.
The 2026 Process Train Thai API Plants Actually Run
Designing a 2026 Thai pharmaceutical ETP means walking through six unit operations in a fixed order. Skipping or reordering stages produces a train that looks defensible on paper but fails on the discharge report. The flow below reflects what is operating in 2026 across the Eastern Seaboard cluster.
Stage 1 — Equalization. HRT 8–12 h, mechanical mixing, online pH and temperature trim, and surge capacity sized to absorb the longest batch campaign in the plant's production schedule. This stage is what keeps downstream biology from being killed by a pH or solvent pulse.
Stage 2 — DAF / primary clarification. A dissolved air flotation unit or lamella clarifier operating at 20–40 m/h surface loading strips TSS, oil & grease, and a meaningful fraction of suspended APIs before biology. Coagulant (typically PAC or ferric chloride) and flocculant dosing are controlled from a PLC-controlled chemical dosing skid for predictable OPEX. A DAF / primary clarification unit with proper lamella geometry reduces chemical consumption by up to 30% versus a conventional clarifier.
Stage 3 — Anaerobic (UASB or IC). HRT 24–48 h, COD removal 60–75%, biogas capture that offsets aeration power downstream. A UASB or internal-circulation reactor handles the high-COD load economically and reduces sludge yield compared to a purely aerobic train.
Stage 4 — Aerobic MBR. MLSS 8,000–12,000 mg/L, SRT 20–40 days, submerged PVDF membranes at 0.1 μm. An integrated MBR system with replaceable DF-series flat sheet MBR cassettes delivers 80–90% API reduction (Zhao et al., 2014) at roughly 60% of the footprint of conventional activated sludge. For Thai plants with space constraints inside an existing estate, this is the unit that earns its capex back in land saved.
Stage 5 — Polishing AOP / UV. UV/H₂O₂ or ozone to break down recalcitrant APIs that pass through biology. AOPs achieve >90% removal for diclofenac and ibuprofen (Yuan et al., 2019), and the same UV reactors that polish for API removal also deliver disinfection, which keeps the residual chlorine requirement off the table. Compact, high-intensity UV/AOP skids sized for the residual API load — not just for disinfection log-credit — are now standard on Thai API ETPs.
Stage 6 (optional) — RO for reuse. Industrial RO polishers sized after MBR + AOP reach recovery of 90–95% with feedwater SDI ≤3. Permeate is suitable for cooling-tower make-up, CIP rinses, and boiler feed after final polishing. RO is not a discharge compliance stage; it is a water-recovery stage, and it only makes economic sense if Stages 1–5 are already performing.
| Stage | Unit operation | Key parameter | Typical target |
|---|---|---|---|
| 1 | Equalization | HRT | 8–12 h |
| 2 | DAF / lamella | Surface loading | 20–40 m/h |
| 3 | UASB / IC anaerobic | COD removal | 60–75% |
| 4 | Submerged MBR | MLSS / SRT | 8,000–12,000 mg/L / 20–40 d |
| 4 | MBR API removal | API reduction | 80–90% |
| 5 | AOP / UV polish | API oxidation | >90% (diclofenac, ibuprofen) |
| 6 | RO reuse | Recovery | 90–95% |
Matching Treatment Technology to Your Influent Profile
No two Thai pharmaceutical plants are the same. A formulation-only plant in Samut Prakan that handles tablets and liquids is not the same problem as an API synthesis plant in Rayong running multi-step organic chemistry with solvent recovery, and neither looks like a biotech facility running fermentation broth. The technology decision flows from the influent profile, not from a generic flowsheet.
| Technology | API removal | Capex band | Footprint | OPEX driver | Best-fit influent |
|---|---|---|---|---|---|
| MBR (PVDF submerged) | 80–90% (Zhao et al., 2014) | Mid–high | Compact (~60% of CAS) | Membrane replacement, aeration | All Thai API profiles; default Stage 4 |
| Activated carbon (GAC) | >70% (Huang et al., 2018) | Low–mid | Mid | Spent carbon disposal | Polishing of formulation effluent |
| Constructed wetlands | >85% (Vymazal, 2011) | Low | Land-hungry | Vegetation upkeep | Rarely viable on Thai industrial estate land |
| AOP (UV/H₂O₂, O₃) | >90% recalcitrant APIs (Yuan et al., 2019) | High | Compact | H₂O₂ / O₃, lamp energy | Required after MBR for API synthesis plants |
| RO | >95% dissolved species | High | Compact | Energy, membrane CIP | Reuse, not compliance |
The decision rule is straightforward. A formulation-only plant with low solvent loading can be defended on EQ + DAF + MBR + UV, and many in Thailand run exactly that train. An API synthesis plant with solvent streams needs anaerobic + MBR + AOP because biological treatment alone will not oxidize the recalcitrant fraction. A biotech plant with fermentation broth needs nutrient removal (TN/TP) added after MBR. The EPA's 2021 finding that over 40% of WWTPs struggle to remove pharmaceuticals effectively is the underlying reason that biological-only trains are now non-defensible for Thai API discharges — the BOD number may pass while the toxicity test fails. For a deeper OPEX view of Stage 4, see this MBR OPEX breakdown for 2026.
Reuse Economics: Turning the ETP Into a Water Asset
In 2026, the CFO conversation in a Thai pharmaceutical boardroom is about water reuse, not compliance. Compliance is the entry ticket; reuse is the return on capex. A 500 m³/day plant with MBR + AOP + RO at 95% recovery reuses roughly 475 m³/day as cooling-tower make-up or CIP rinse water, displacing the corresponding volume of fresh industrial water purchase. At 2026 Thai industrial water tariffs and with cooling-tower chemistry on the permeate side already proven, typical RO retrofit payback after MBR/AOP lands in the 18–36 month range, with the wider band driven by influent salinity, hours of operation, and whether the permeate feeds a high-pressure boiler or a low-pressure cooling loop.
| Item | Typical 2026 value | Notes |
|---|---|---|
| RO recovery (after MBR + AOP) | 90–95% | Feed SDI ≤3 required |
| Daily reuse (500 m³/d plant) | ~475 m³/d | Cooling-tower make-up, CIP, boiler feed |
| RO retrofit payback | 18–36 months | Site-specific, driven by tariff and permeate use |
| Chemical savings from lamella DAF | Up to 30% | High-efficiency sedimentation tank geometry |
| Biogas offset (UASB) | 0.3–0.4 m³ CH₄/kg COD removed | Offsets aeration power downstream |
Upstream, the DAF stage is where the OPEX discipline starts. A high-efficiency sedimentation tank with proper lamella geometry cuts coagulant and flocculant use by up to 30%, which compounds across years of operation. The 2026 case for a Thai API plant to upgrade its ETP is not purely regulatory — it is a water-asset case built around reuse recovery and chemical efficiency.
2026 Factory Buyer Checklist for Thai Pharmaceutical ETPs
Procurement leads running an RFQ in 2026 should not accept a flowsheet without verifying each of the points below. This list is what separates a defensible bid from a lowest-price bid that fails the discharge test in year two.
- Influent characterization first. Confirm batch-by-batch variability, peak flows, and a representative API panel before sizing equalization. A 1,000 m³/d average with 5× peaks needs different EQ than a steady 1,000 m³/d.
- MBR spec. Specify 0.1 μm submerged PVDF with documented 80–90% API reduction and replaceable cassettes. Demand a published membrane life and CIP protocol.
- Chemical dosing. Require skid-mounted, PLC-controlled chemical dosing (coagulant, flocculant, pH, anti-scalant) — a PLC-controlled chemical dosing skid is the only way to keep OPEX predictable across shifts.
- Polishing sized for API load. UV or O₃ polishing must be sized for residual API load, not just disinfection log-credit. Ask for a guaranteed removal figure against the target API panel.
- RO only after MBR/AOP. Target recovery ≥90% and feedwater SDI ≤3. Add a multi-media pre-filter in front of the RO to protect membranes from particulates.
- After-sales. Validate membrane replacement cycles, CIP chemical supply, and local Thai service response time. A two-week membrane shipment from overseas is not acceptable for a plant that discharges daily.
For a broader perspective on how these stages fit into a packaged plant, the Thailand package wastewater treatment plant guide covers the same compliance logic for plants below 200 m³/d. For regional context outside Thailand, the pharmaceutical wastewater treatment in Bahrain guide applies a similar train to Gulf influent profiles.
Frequently Asked Questions
What are the discharge limits for pharmaceutical wastewater in Thailand under the 2026 Thai FDA effluent notification?
The Thai FDA Notification B.E. 2556 (2013), enforced by the Pollution Control Department in 2026, sets BOD ≤20 mg/L, COD ≤120 mg/L, TSS ≤50 mg/L, pH 5.5–9.0, oil & grease ≤5 mg/L, and residual chlorine ≤1 mg/L, with site-specific heavy-metal limits. There is no single numeric API limit; operators are judged on BOD/COD/TSS plus whole-effluent toxicity, which is why AOP polishing is now standard on Thai API ETPs.
Which process train is recommended for a Thai API synthesis plant discharging to a coastal receiver?
A six-stage train — equalization (HRT 8–12 h), DAF or lamella clarification, anaerobic UASB or IC (HRT 24–48 h, 60–75% COD removal), submerged PVDF MBR (80–90% API reduction), UV/H₂O₂ or O₃ AOP (>90% recalcitrant API oxidation), and RO for reuse (90–95% recovery). Coastal discharge to Map Ta Phut outfalls triggers additional TDS scrutiny, which the RO stage resolves.
How much can a Thai pharmaceutical plant save by adding RO reuse after MBR and AOP?
A 500 m³/day plant with MBR + AOP + RO at 95% recovery reuses roughly 475 m³/day as cooling-tower make-up or CIP rinse water. At 2026 Thai industrial water tariffs, RO retrofit payback after MBR/AOP typically lands in the 18–36 month range, with site-specific variation driven by influent salinity, permeate end use, and operating hours.
Why is a biological-only treatment train not sufficient for Thai API discharges in 2026?
EPA 2021 data shows over 40% of WWTPs struggle to remove pharmaceutical compounds effectively. For a Thai API plant, biological treatment alone (even conventional activated sludge) typically leaves the recalcitrant API fraction intact, which then fails whole-effluent toxicity tests even when BOD and COD pass. A polishing AOP/UV stage after MBR is what closes the gap on toxicity and keeps the plant within the Thai FDA notification envelope.
